Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.

Wachter, Franziska; Pikman, Yana; Bledsoe, Jacob; Kapadia, Malika; Baumeister, Susanne; Rowe, Jared; Shimamura, Akiko; Place, Andrew E; Prockop, Susan; Whangbo, Jennifer; Lehmann, Leslie; Horan, John; Pollard, Jessica

Wachter, Franziska; Pikman, Yana; Bledsoe, Jacob; Kapadia, Malika; Baumeister, Susanne; Rowe, Jared; Shimamura, Akiko; Place, Andrew E; Prockop, Susan; Whangbo, Jennifer; Lehmann, Leslie; Horan, John; Pollard, Jessica.

Afiliação

Wachter F; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Pikman Y; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Bledsoe J; Department of Pathology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA.
Kapadia M; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Baumeister S; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Rowe J; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Shimamura A; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Place AE; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Prockop S; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Whangbo J; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Lehmann L; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Horan J; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.
Pollard J; Division of Hematology/Oncology, Department of Pediatric Oncology Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School Boston Massachusetts USA.

Clin Case Rep ; 11(11): e8190, 2023 Nov.

Article em En | MEDLINE | ID: mdl-38028059

ABSTRACT

ABSTRACT

Treatment of recurrent myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) remains challenging. We present a 4-year-old girl experiencing early MDS relapse post-HCT treated with a multimodal strategy encompassing a second HCT and innovative targeted therapies. We underscore the potential of a comprehensive treatment approach in managing recurrent pediatric MDS.

Palavras-chave

disease control; hematopoietic stem cell transplantation; myelodysplastic syndromes; relapse

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Case Rep Ano de publicação: 2023 Tipo de documento: Article